menu
    • menu
    [{"orgOrder":0,"company":"Entheon Biomedical","sponsor":"Laboratorium Ofichem B.V","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Entheon Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entheon Biomedical \/ Ofichem Laboratorium","highestDevelopmentStatusID":"7","companyTruncated":"Entheon Biomedical \/ Ofichem Laboratorium"},{"orgOrder":0,"company":"Entheon Biomedical","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Deuterated Dimethyltryptamine","moa":"Serotonin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Entheon Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Entheon Biomedical \/ Cybin","highestDevelopmentStatusID":"6","companyTruncated":"Entheon Biomedical \/ Cybin"},{"orgOrder":0,"company":"Entheon Biomedical","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Entheon Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entheon Biomedical \/ Cybin IRL Limited","highestDevelopmentStatusID":"6","companyTruncated":"Entheon Biomedical \/ Cybin IRL Limited"}]

    Find Clinical Drug Pipeline Developments & Deals by Entheon Biomedical

    Menu

    Entheon Biomedical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Entheon Biomedical

                            India arrow
                            2024 ACI Convention
                            Not Confirmed

                            Entheon Biomedical

                            India arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Deuterated Dimethyltryptamine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Cybin

                            Deal Size : $1.1 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical

                            Details : This DMT study, which is the largest to date, is expected to accelerate the clinical development path of CYB004, Cybin’s proprietary deuterated DMT molecule for the potential treatment of anxiety disorders, by approximately nine months.

                            Brand Name : CYB004

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 11, 2022

                            Lead Product(s) : Deuterated Dimethyltryptamine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Cybin

                            Deal Size : $1.1 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Entheon Biomedical

                            India arrow
                            2024 ACI Convention
                            Not Confirmed

                            Entheon Biomedical

                            India arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Deuterated Dimethyltryptamine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Cybin

                            Deal Size : $1.2 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Cybin Acquires DMT Clinical Study from Entheon Biomedical

                            Details : Pending the close of the Acquisition, the CYB004-E study is expected to yield essential safety and dosing optimization data and will replace Cybin’s planned pilot study for CYB004 that was expected to commence in the third quarter of 2022.

                            Brand Name : CYB004

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 07, 2022

                            Lead Product(s) : Deuterated Dimethyltryptamine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Cybin

                            Deal Size : $1.2 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Entheon Biomedical

                            India arrow
                            2024 ACI Convention
                            Not Confirmed

                            Entheon Biomedical

                            India arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dimethyltryptamine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Laboratorium Ofichem B.V

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Entheon Biomedical Provides Update on Clinical and Preclinical DMT Programs

                            Details : Formulation and stability testing of DMT drug product by CHDR's partner pharmacy has commenced in accordance with projected start date of EBRX-101(N, N-dimethyltryptamine), a study that will evaluate controlled intravenous infusion of population of healt...

                            Brand Name : EBRX-101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 24, 2021

                            Lead Product(s) : Dimethyltryptamine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Laboratorium Ofichem B.V

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth